MedTrace Logo

Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma

NCT03821077 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 122

Last updated 2021-10-20

No results posted yet for this study

Summary

This is an observational prospective multicenter clinical study, to evaluate the efficacy and safety of the treatment with Allergovac Poliplus subcutaneous immunotherapy (SCIT) with a mixture of 2 allergenic extracts (pollens or mites), in polymerized-depot formulation, administered in its different available allergenic extracts mixtures (2 pollens or 2 mites), and in one of the 2 recommended administration schedules (1 Day or Rapid).

Conditions

  • Rhinitis, Allergic
  • Rhinoconjunctivitis

Interventions

BIOLOGICAL

Allergen Immunotherapy (AIT)

Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation

Sponsors & Collaborators

  • Roxall Medicina España S.A

    lead INDUSTRY

Eligibility

Min Age
5 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-30
Primary Completion
2021-09-13
Completion
2021-09-13

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03821077 on ClinicalTrials.gov